Literature DB >> 3409244

Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration.

M M Gottardis1, V C Jordan.   

Abstract

Long-term tamoxifen (TAM) therapy was examined in athymic mice bearing MCF-7 tumors of different sizes. Six months of TAM treatment caused no increase in tumor size (compared to placebo treatment) for animals treated initially following implantation of tumor pieces (approximately 1 mm3) or for animals with 0.2-cm2 tumors (grown with 1 month of estrogen treatment). Tumors could be regrown with estradiol treatment in animals treated with either therapy and these tumors contained both estrogen and progesterone receptors. However, more tumors could be restimulated with estradiol following pretreatment with TAM than with placebo. A third group of animals had larger tumors (grown with 7 weeks of estrogen treatment to a approximately 0.6-cm2 area) before TAM or placebo treatment. These tumors partially regressed after 4 months of TAM or placebo therapy but began to regrow in both groups until the end of the experiment at 8 months. Tumors that grew in both groups were estrogen receptor positive and when retransplanted into athymic animals could grow with estradiol. However, the tumor that grew during TAM therapy, when retransplanted, could grow successfully only with further TAM treatment. Tumors growing with TAM contained double the estrogen receptor content of the estradiol-stimulated MCF-7 tumors that were not exposed to TAM [390 +/- 37 (SE) fmol/mg protein versus 174 +/- 14 fmol/mg protein]. These results may represent a form of TAM resistance, i.e., TAM dependence that may occur before hormone independence is exhibited.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3409244

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  103 in total

1.  Raloxifene: handle with care.

Authors:  K I Pritchard; M Levine; B Walley
Journal:  CMAJ       Date:  2001-07-24       Impact factor: 8.262

Review 2.  The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer.

Authors:  Donald P McDonnell; Suzanne E Wardell
Journal:  Curr Opin Pharmacol       Date:  2010-12       Impact factor: 5.547

Review 3.  Solving the puzzle of hormone-dependent breast cancer.

Authors:  R J Santen
Journal:  Trans Am Clin Climatol Assoc       Date:  1992

4.  Profile of V. Craig Jordan.

Authors:  Sujata Gupta
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-16       Impact factor: 11.205

5.  Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.

Authors:  V Craig Jordan; Ramona Curpan; Philipp Y Maximov
Journal:  J Natl Cancer Inst       Date:  2015-04-02       Impact factor: 13.506

Review 6.  Exploiting the apoptotic actions of oestrogen to reverse antihormonal drug resistance in oestrogen receptor positive breast cancer patients.

Authors:  V Craig Jordan; Joan Lewis-Wambi; Helen Kim; Heather Cunliffe; Eric Ariazi; Catherine G N Sharma; Heather A Shupp; Ramona Swaby
Journal:  Breast       Date:  2007-08-24       Impact factor: 4.380

7.  Acquired resistance to selective estrogen receptor modulators (SERMs) in clinical practice (tamoxifen & raloxifene) by selection pressure in breast cancer cell populations.

Authors:  Ping Fan; V Craig Jordan
Journal:  Steroids       Date:  2014-06-12       Impact factor: 2.668

8.  Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease.

Authors:  Suzanne E Wardell; Erik R Nelson; Christina A Chao; Donald P McDonnell
Journal:  Clin Cancer Res       Date:  2013-03-27       Impact factor: 12.531

Review 9.  Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.

Authors:  Jing Peng; Surojeet Sengupta; V Craig Jordan
Journal:  Anticancer Agents Med Chem       Date:  2009-06       Impact factor: 2.505

10.  Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells.

Authors:  Robert Clarke; Ayesha N Shajahan; Rebecca B Riggins; Younsook Cho; Anatasha Crawford; Jianhua Xuan; Yue Wang; Alan Zwart; Ruchi Nehra; Minetta C Liu
Journal:  J Steroid Biochem Mol Biol       Date:  2009-03       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.